Is 9103 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 9103 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 9103's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 9103's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 9103?
Key metric: As 9103 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
The above table shows the Price to Sales ratio for 9103. This is calculated by dividing 9103's market cap by their current
revenue.
What is 9103's PS Ratio?
PS Ratio
1x
Sales
US$51.63m
Market Cap
US$53.41m
9103 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Sales vs Industry: 9103 is good value based on its Price-To-Sales Ratio (1x) compared to the TW Medical Equipment industry average (2.8x).
Price to Sales Ratio vs Fair Ratio
What is 9103's PS Ratio
compared to its
Fair PS Ratio?
This is the expected PS Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
9103 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio
1x
Fair PS Ratio
n/a
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 9103's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.